Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
By Agnes Y. Y. Lee, M. Levine, R. Baker, C. Bowden, A. Kakkar, M. Prins, F. Rickles, J. Julian, S. Haley, M. Kovacs and 1 more. New England Journal of Medicine, 2003
2,379 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hematology, Internal Medicine
View Paper: https://www.semanticscholar.org/paper/169afcb0b8d1195d3dd1f4c2bee371219a10c0b2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Hematology
In Internal Medicine
Citations in the corpus
- 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) (2019, background): “364 In 2003, a significant reduction in VTE recurrence was reported with LMWH compared with conventional (VKA) treatment without an increase in bleeding complications.(362) In a more recent trial, long-term administration of tinzaparin failed to achieve a statistically significant reduction in overa”
- Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study (2006, background): “For cancer patients, incidences of major bleeding of 4–7.5% in 6 months during treatment with low-molecular-weight heparins or oral anticoagulants have been reported [14, 19 ].”
- Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism (2008, background): “It is, however, higher in patients with idiopathic VTE.”